Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study-Reference-Cited by-同舟云学术

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Published:2020-02 Issue:2 Volume:82 Page:377-388
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Deleuran Mette,Thaçi Diamant,Beck Lisa A.,de Bruin-Weller Marjolein,Blauvelt Andrew,Forman Seth,Bissonnette Robert,Reich Kristian,Soong Weily,Hussain Iftikhar,Foley Peter,Hide Michihiro,Bouaziz Jean-David,Gelfand Joel M.,Sher Lawrence,Schuttelaar Marie L.A.,Wang Chen,Chen Zhen,Akinlade Bolanle,Gadkari Abhijit,Eckert Laurent,Davis John D.,Rajadhyaksha Manoj,Staudinger Heribert,Graham Neil M.H.,Pirozzi Gianluca,Ardeleanu Marius

Funder

Sanofi

Regeneron Pharmaceuticals

Celgene

Novartis

Sanofi Genzyme

AstraZeneca

Lilly

Incyte

Janssen

Promius

Pfizer

Valeant

AbbVie

Aquinox Pharma

Arcutis Antiobix

Asana

Astellas

Boehringer Ingelheim

Brickell Biotech

Dermavant

Dermira

Dignity Sciences

Galderma

Glenmark

GlaxoSmithKline

Hoffman-La Roche

Kiniksa

LEO Pharma

Neokera

Ralexar

Vitae

Aimmune

Circassia

Genentech

LEO Pharma

Menlo Therapeutics

Optinose

Roche

Stallergenes

Teva

Amgen

BMS

Celtaxsys

Cutanea

Merck

Sun Pharma

UCB

Kaken Pharmaceutical

Kyowa Hakko Kirin

Mitsubishi-Tanabe

Merck Sharp & Dohme

Taiho Pharmaceutical

Teikoku Seiyaku

Therakos

University of Pennsylvania

Publisher

Elsevier BV

Subject

Dermatology

Reference41 articles.

1. Atopic dermatitis;Weidinger;Lancet,2016

2. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study;Silverberg;J Allergy Clin Immunol,2013

3. Addressing treatment challenges in atopic dermatitis with novel topical therapies;Silverberg;J Dermatolog Treat,2016

4. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis;Gittler;J Allergy Clin Immunol,2012

5. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies;Boguniewicz;J Allergy Clin Immunol Pract,2017

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study;Children;2024-01-28

2. Real-world efficacy of dupilumab re-administration after discontinuation in patients with atopic dermatitis;Journal of Cutaneous Immunology and Allergy;2024-01-22

3. An Era of Therapeutic Evolution and Revolution: Insights into Studies on Dupilumab, Tralokinumab, Lebrikizumab, Nemolizumab, Eblasakimab, and OX40/OX40L Agents (Rocatinlimab and Amlitelimab) in Moderate-to-Severe Atopic Dermatitis;Recent Advances in the Treatment of Atopic Dermatitis [Working Title];2024-01-19

4. Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors;American Journal of Clinical Dermatology;2024-01-12

5. Targeting fusion proteins of the interleukin family: A promising new strategy for the treatment of autoinflammatory diseases;European Journal of Pharmaceutical Sciences;2024-01